Geron Corp Sustainability Reports
Geron Corporation is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics for myeloid hematologic malignancies. Its primary product is imetelstat (Rytelo), a telomerase inhibitor used in the treatment of myelodysplastic syndromes.
Sector: Manufacturing
Country: United States
Exchange: Nasdaq
LEI: 549300T282D7Z2YESL90
FIGI: BBG001S6TSX4
17 reports from 2006 to 2025
